FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1766366107> ?p ?o ?g. }

• W1766366107 endingPage "34" @default.
• W1766366107 startingPage "22" @default.
• W1766366107 abstract "Background and Objective: Pomalidomide - a combination of Lenalidomide and Thalidomide drugs- is one of the newest anticancer drugs. Pomalidomide induces apoptosis in cancer cells. Furthermore, few studies indicating its relatively low cytotoxic effects on normal peripheral blood cells have been carried out. However, there is yet no information about the effects of Pomalidomide on bone marrow cells that contain important immune cells. In this study, the effect of Pomalidomide on normal bone marrow mononuclear cells was studied. Materials and Methods: The samples obtained from individuals who clinically needed bone marrow examination, but finally were diagnosed with no serious pathologic conditions in their leukocytes. Remained bone marrow aspirates were obtained and mononuclear cells were isolated. Half of the mononuclear cells were cultured with Pomalidomide (final concentration 10μM) and the remaining half (control group) were cultured with media alone. After 48h incubation, vital activity (MTT) and cell apoptosis induction rates were assessed. Results: The results showed that the vital activity of bone marrow mononuclear cells cultured in the presence of Pomalidomide increased significantly compared to the control group (P less-than 0.05). However, Pomalidomide had no apoptosis induction and the rate of apoptotic cells had no significant difference with control group. Conclusion: Pomalidomide moderately stimulates the viability (or activity) of normal bone marrow mononuclear cells to improve and maintain them. Also, unlike most anticancer drugs it has no observable toxic effect or apoptosis induction on these cells. So, it may be concluded that Pomalidomide may be more favorable in preventing the side effects of anticancer drugs on normal cells. References 1- Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007 39(7): 1489-99. 2- Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 24(1): 22-32. 3- Shalapour S, Zelmer A, Pfau M, et al. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells invitro and invivo. Clin Cancer Res. 2006 12(18): 5526-32. 4- Baskic D, Popovic S, Ristic P, Arsenijevic NN. Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int. 2006 30(11): 924-32. 5- Lacy MQ. New immunomodulatory drugs in myeloma. Curr Hematol Malig Rep. 2011 6(2): 120-5. 6- Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012 36(10): 1218-24. 7- Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 116(17): 3227-37. 8- Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs. 2011 20(5): 691-700. 9- Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 305(3): 1222-32. 10- Marriott J, Clarke I, Dredge K, Muller G, Stirling D, Dalgleish A. Thalidomide and its analogues have distinct and opposing effects on TNF- α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin & Exp Immunol. 2002 130(1): 75-84. 11- Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma. 2011 52(4): 560-6. 12- Ahmadbeigi N, Soleimani M, Mortazavi Y. The efficiency of density gradient for separation of mesenchymal stem cells from bone marrow sample. Zanjan Unv Med Sci J. 2011 19 (77): 62-69. 13- Hernandez P, Cortina L, Artaza H, et al. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: A comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis. 2007 194(2): e52-e6. 14- Hay FC, Westwood OM. Practical immunology 4th edition. UK: Wiley 2008. 15- Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013 122(14): 2305-9. 16- Chanan-Khan A, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013 3(9): e143. 17- Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004 4(4): 314-22. 18- Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 122(1): 1-6. 19- Nicholas A, Boon MA, Nicki R, Brian R, Walker JA, Hunter D. Principle And practice of medicine. 20th Edition. UK: Churchill Livingstone 2006. 20- Liu W, Henry J, Meyer B, Bartlett J, Dalgleish A, Galustian C. Inhibition of metastatic potential in colorectal carcinoma invivo and invitro using immunomodulatory drugs (IMiDs). Br J Cancer. 2009 101(5): 803-12. 21- Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008 118(1): 248-58. 22- Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 27: 4563-9." @default.
• W1766366107 created "2016-06-24" @default.
• W1766366107 creator A5013460672 @default.
• W1766366107 creator A5059788507 @default.
• W1766366107 creator A5079854168 @default.
• W1766366107 creator A5088516849 @default.
• W1766366107 date "2014-07-01" @default.
• W1766366107 modified "2023-09-26" @default.
• W1766366107 title "THE EFFECT OF ANTICANCER POMALIDOMIDE DRUG ON VITAL ACTIVITY AND APOPTOSIS INDUCTION ON BONE MARROW MONONUCLEAR CELLS" @default.
• W1766366107 cites W1544336360 @default.
• W1766366107 cites W1597238753 @default.
• W1766366107 cites W1977046091 @default.
• W1766366107 cites W1986796600 @default.
• W1766366107 cites W2024305952 @default.
• W1766366107 cites W2030904288 @default.
• W1766366107 cites W2037834319 @default.
• W1766366107 cites W2058009067 @default.
• W1766366107 cites W2071760555 @default.
• W1766366107 cites W2072753134 @default.
• W1766366107 cites W2097860477 @default.
• W1766366107 cites W2133739087 @default.
• W1766366107 cites W2147890019 @default.
• W1766366107 hasPublicationYear "2014" @default.
• W1766366107 type Work @default.
• W1766366107 sameAs 1766366107 @default.
• W1766366107 citedByCount "0" @default.
• W1766366107 crossrefType "journal-article" @default.
• W1766366107 hasAuthorship W1766366107A5013460672 @default.
• W1766366107 hasAuthorship W1766366107A5059788507 @default.
• W1766366107 hasAuthorship W1766366107A5079854168 @default.
• W1766366107 hasAuthorship W1766366107A5088516849 @default.
• W1766366107 hasConcept C137061746 @default.
• W1766366107 hasConcept C154317977 @default.
• W1766366107 hasConcept C185592680 @default.
• W1766366107 hasConcept C190283241 @default.
• W1766366107 hasConcept C202751555 @default.
• W1766366107 hasConcept C203014093 @default.
• W1766366107 hasConcept C2776063141 @default.
• W1766366107 hasConcept C2776364478 @default.
• W1766366107 hasConcept C2778524551 @default.
• W1766366107 hasConcept C2779609412 @default.
• W1766366107 hasConcept C2780007613 @default.
• W1766366107 hasConcept C502942594 @default.
• W1766366107 hasConcept C55493867 @default.
• W1766366107 hasConcept C71924100 @default.
• W1766366107 hasConcept C98274493 @default.
• W1766366107 hasConceptScore W1766366107C137061746 @default.
• W1766366107 hasConceptScore W1766366107C154317977 @default.
• W1766366107 hasConceptScore W1766366107C185592680 @default.
• W1766366107 hasConceptScore W1766366107C190283241 @default.
• W1766366107 hasConceptScore W1766366107C202751555 @default.
• W1766366107 hasConceptScore W1766366107C203014093 @default.
• W1766366107 hasConceptScore W1766366107C2776063141 @default.
• W1766366107 hasConceptScore W1766366107C2776364478 @default.
• W1766366107 hasConceptScore W1766366107C2778524551 @default.
• W1766366107 hasConceptScore W1766366107C2779609412 @default.
• W1766366107 hasConceptScore W1766366107C2780007613 @default.
• W1766366107 hasConceptScore W1766366107C502942594 @default.
• W1766366107 hasConceptScore W1766366107C55493867 @default.
• W1766366107 hasConceptScore W1766366107C71924100 @default.
• W1766366107 hasConceptScore W1766366107C98274493 @default.
• W1766366107 hasIssue "94" @default.
• W1766366107 hasLocation W17663661071 @default.
• W1766366107 hasOpenAccess W1766366107 @default.
• W1766366107 hasPrimaryLocation W17663661071 @default.
• W1766366107 hasRelatedWork W1411722693 @default.
• W1766366107 hasRelatedWork W2073040868 @default.
• W1766366107 hasRelatedWork W2384953742 @default.
• W1766366107 hasRelatedWork W2395524987 @default.
• W1766366107 hasRelatedWork W2439803058 @default.
• W1766366107 hasRelatedWork W2558266360 @default.
• W1766366107 hasRelatedWork W2565282098 @default.
• W1766366107 hasRelatedWork W2586470883 @default.
• W1766366107 hasRelatedWork W2588030565 @default.
• W1766366107 hasRelatedWork W2785259311 @default.
• W1766366107 hasRelatedWork W2912240505 @default.
• W1766366107 hasRelatedWork W2983129027 @default.
• W1766366107 hasRelatedWork W2983145331 @default.
• W1766366107 hasRelatedWork W2983979814 @default.
• W1766366107 hasRelatedWork W2988397338 @default.
• W1766366107 hasRelatedWork W2988512835 @default.
• W1766366107 hasRelatedWork W2988522122 @default.
• W1766366107 hasRelatedWork W2991403069 @default.
• W1766366107 hasRelatedWork W3022123725 @default.
• W1766366107 hasRelatedWork W3024463515 @default.
• W1766366107 hasVolume "22" @default.
• W1766366107 isParatext "false" @default.
• W1766366107 isRetracted "false" @default.
• W1766366107 magId "1766366107" @default.
• W1766366107 workType "article" @default.